Blog posts

Supporting the safe and meaningful involvement of women experiencing homelessness in research

Imperial’s Institute of Global Health Innovation is collaborating with the Marylebone Project and Central London Healthcare on a pioneering project funded by the National Institute for Health and Care Research (NIHR). This 18-month initiative focuses on supporting the safe and meaningful involvement of women experiencing homelessness in research. By prioritizing trauma-informed, psychologically supportive practices, the project seeks to improve research methods, ensure participant safety, and empower women to share their experiences. This approach aims to enhance healthcare for this vulnerable group while driving positive change in research and policy.
Members of the research team from IGHI and the Marylebone Project having lunch

Imperial’s Institute of Global Health Innovation (IGHI) is collaborating with the Marylebone Project and Central London Healthcare on a pioneering project funded by the National Institute for Health and Care Research (NIHR). This 18-month initiative focuses on supporting the safe and meaningful involvement of women experiencing homelessness in research. The project seeks to improve research methods, ensure participant safety, and empower women to share their experiences.

IGHI recently received funding from the National Institute of Health and Care Research (NIHR) for an 18-month project in partnership with the Marylebone Project and Central London Healthcare which focuses on supporting the safe and meaningful involvement of women experiencing homelessness in research.

People experiencing homelessness have shorter life expectancies, poorer physical and mental health, and less access to healthcare than the general population. For women experiencing homelessness, the average age of death is 43 – two years younger than men and nearly half the life expectancy of women in the general population. Many homeless women are survivors of abuse, and more research is needed to provide specialised, female-led support for this group in safe, trauma-informed spaces.

(more…)

Call for vigilance after fertility treatment

Dr Srdjan Saso

Fertility treatments like IVF help thousands of women achieve their dream of motherhood each year, but what are the long-term health implications? Dr Srdjan Saso, Honorary Clinical Senior Lecturer in the Department of Metabolism, Digestion and Reproduction and Consultant Gynaecologist and Gynaecological Cancer Surgeon at Imperial College Healthcare NHS Trust, explores what the data reveals, and how clinics can improve long-term health monitoring.

As a gynaecological cancer surgeon, I see many women diagnosed with cancers who I know are also concerned about protecting their fertility. Societal pressures, evolving gender roles, financial insecurities, but most importantly, in my opinion, a declining cultural emphasis of motherhood are leading to delayed childbearing and lower fertility rates.

Fertility treatments, such as in vitro fertilization (IVF), help many thousands of women conceive every year. With colleagues from Imperial and KU Leuven, I set out on a collaborative research project to explore an important question: could undergoing fertility treatment influence the risk of developing certain gynaecological cancers?

(more…)

Imperial College medical student receives The Diana Award

Haroop BolaFinal year medical student, Harroop Bola, and Founding Chair of the British Indian Medical Association, which received the Diana Award last year, shares how the association fosters mentorship, education, and leadership for medical professionals from Widening Participation backgrounds. He highlights BIMA’s impactful initiatives, from academic workshops to community support, inspiring the next generation of changemakers in the NHS and global healthcare. 

I am delighted to share that my work with the British Indian Medical Association has been honoured with the Diana Award 2024- the highest accolade a young person can achieve for social action or humanitarian efforts. Established in memory of Diana, Princess of Wales, the award is given out by the charity of the same name and has the support of both her sons, HRH The Prince of Wales and Prince Harry, The Duke of Sussex. 

Joining Imperial College London’s School of Medicine as a first-generation university student without established connections in medicine was an intimidating journey. While access to medical school has improved through widening participation initiatives, the systemic challenges remain; opportunities within medicine often favour those with access to high-quality mentorship. With approximately one-third of medical students coming from medical families and competition for training posts increasing annually, mentorship has become an invaluable asset. For individuals like me, navigating the complexities of a medical career and building a competitive portfolio without prior insight into the profession can feel overwhelming.  

Harroop Bola delivering a speech during the 3rd Annual BIMA Conference at Imperial College London
Figure 1: Harroop Bola delivering a speech during the 3rd Annual BIMA Conference at Imperial College London

During the height of the COVID-19 pandemic, as I transitioned from my first to second year of medical school, I joined forces with Dr Amar Rai and Virensinh Rathod to establish the British Indian Medical Association (BIMA). Our vision was simple yet powerful: to foster a sense of community within the medical field and leverage collective support to address gaps in education, mentorship, and cultural identity. 

(more…)

Fleming’s Final Flourish

Professor John Tregoning, Professor of Vaccine Immunology in the Department of Infectious Disease, explores the legacy of Sir Alexander Fleming and the urgent fight against antimicrobial resistance. From the historic discovery of penicillin at St Mary’s Medical School to the ambitious Fleming Initiative, Professor Tregoning discusses how a groundbreaking new centre aims to tackle one of the greatest challenges in modern medicine.

If you were watching the Royal Institution (RI) Christmas Lectures with Dr Chris van Tulleken, you will have seen two plates of food disintegrate into a mushy goo. This was filmed at the St Mary’s Medical School Building in Paddington, London. In fact, it was probably the last ever experiment done in this hallowed building. In some ways it seems appropriate that it involved mould. St Mary’s will always be famous as the site of where Sir Alexander Fleming performed his breakthrough studies. Or as he modestly put it: ‘revolutionize all medicine by discovering the world’s first antibiotic’. 

(more…)

Exploring new frontiers in coronary heart disease research

Dr Rasha Al-Lamee

This festive period, Three Wise Women from the Faculty of Medicine will be giving us the gift of wisdom.

Dr Rasha Al-Lamee, Clinical Reader in the National Heart & Lung Institute and Clinical Academic Interventional Cardiology Consultant at Imperial College Healthcare NHS Trust, highlights the unique strengths of the UK’s life sciences research ecosystem, from the NHS to the invaluable contributions of patients. She reflects on her groundbreaking ORBITA trials, which challenged conventional wisdom about stenting for coronary artery disease. Dr Al-Lamee also shares how these experiences have shaped her career and passion for mentoring the next generation of cardiologists.

We are fortunate in the UK to have a well-developed infrastructure for research in life sciences. Our universal healthcare system within the NHS, world-leading academic institutions, and dedicated researchers provide a unique environment for innovation. Most importantly, it is our incredible patients—who not only understand the need for research but are willing to participate—that make groundbreaking studies possible. This unique combination allows us to lead the world in delivering research that tests novel treatments, evaluates existing practices, and paves the way for guideline-changing clinical practice.

As a clinical trialist, I have been privileged to work within this exceptional ecosystem. It has allowed me to carry out work that I do not believe could have been conducted in many other places in the world. My focus has been on treatments for ‘stable’ coronary artery disease, a condition that affects around 2.3 million people in the UK and causes chest pain, breathlessness, and sometimes pain throughout the body. Treatments often include medicines or angioplasty, a procedure where stents—wire mesh tubes—are placed into arteries to open blockages. However, since its introduction, there has been ongoing debate about whether the relief patients experience is due to the procedure itself or a placebo effect.

(more…)

Beyond survival: Why cancer survivorship matters

Professor Pernilla Lagergren

This festive period, Three Wise Women from the Faculty of Medicine will be giving us the gift of wisdom.

When cancer treatment ends, a new journey begins—one filled with unique challenges. Professor Pernilla Lagergren, Chair in Surgical Care Sciences at the Department of Surgery and Cancer, explores what life is like after cancer treatment. Drawing on her clinical experience with oesphageal and gastric cancer patients, she shares how her survivorship research is helping to shape better outcomes for patients, their families, and the healthcare system. 

When people think about cancer, they often focus on the illness itself—the diagnosis, the treatments, and the fight to survive. But once the treatment ends, another important challenge begins: what happens after cancer? As a researcher in cancer survivorship, my focus is on understanding what life is like for people who have been treated for cancer, and how we can improve that life for them. 

Here, I’ll explore the significance of cancer survivorship research, the insights we’ve gained, and what drives my commitment to this field. I‘ll also highlight how my work contributes to improving the lives of cancer survivors, supporting their families, and strengthening the healthcare system. 

(more…)

When science meets serendipity: How accidental discoveries could revolutionise women’s health

Professor Aylin Hanyaloglu

This festive period, Three Wise Women from the Faculty of Medicine will be giving us the gift of wisdom.

Aylin Hanyaloglu, Professor in Molecular Medicine in the Department of Metabolism, Digestion and Reproduction, reflects on the role of serendipity in both scientific discovery and her own 17-year research career at Imperial. She explores how unexpected findings—like those in her team’s research on G protein-coupled receptors (GPCRs)—can lead to breakthroughs that shape the future of medicine. From fertility treatments to the quest for more precise drugs, Aylin discusses how curiosity and embracing the unexpected have driven her team’s progress.

Serendipity—the fact of finding valuable or interesting things by chance—has long been a key element in scientific research. This is exemplified by Sir Alexander Fleming’s accidental discovery of penicillin, which revolutionised medicine: “I did not invent penicillin. Nature did that. I only discovered it by accident.” With this definition, serendipity for me has played a significant role in both the discoveries in our research as well as my career journey. This time of year offers opportunities to reflect on different areas in our lives, and I have often used the term serendipity for describing my journey. But what do I mean by this? Is it needed or just a normal part of the discovery process? And with the rapidly evolving landscape of how science is conducted, will this continue? 

(more…)

World AIDS Day 2024: ‘Take the rights path’

Sarah Fidler and Jonas Bergmann Poulsen

To mark World AIDS Day, Professor Sarah Fidler from the Department of Infectious Disease, and student, Jonas Bergmann from the University of Amsterdam, reflect on the evolution of HIV treatment and the ongoing challenges. They discuss the impact of stigma, the importance of accessible medication, and the role of community-led initiatives in supporting those living with HIV. 

Professor Sarah Fidler

My first experience of HIV was in 1988 when I was 24 years old. I had just qualified as a junior doctor.  As I started work on the respiratory ward, there were several young people who were inpatients. This was unusual for an acute medical ward, which treats patients with urgent medical conditions. Our patients were a similar age to me, but these young people – who should have had their whole lives ahead of them were isolated, sick and dying.  

 Not only were they dying, but they were dying with a health condition that also affected their partners, all while  facing fear, judgement and stigmatisation. As a result, many had no family with them to help ease their passing – just prejudice, homophobia and ignorance. We had no medicines that could reverse the medical complications, nothing that could make them better. All we could do was to care for them as best we could, providing empathy, kindness and medical support to ease their journey.  

(more…)

How medicine and medical research has contributed to HIV stigma–and how we challenge it

Alan Winston

World AIDS Day is a vital opportunity to raise awareness about HIV/AIDS and honour those whose lives have been affected by the disease. Professor Alan Winston from the Department of Infectious Disease explores how language and scientific definitions have contributed to the stigmatisation of those living with the disease and emphasises the need for person-centred language and thoughtful scientific communication to reduce discrimination in medicine and medical research. 

The initial fear 

Since AIDS–Acquired Immune Deficiency Syndrome–was first identified in the 1980s, along with its underlying cause–the Human Immune Deficiency virus (HIV)– people living with HIV have encountered immense discrimination and stigma. Whilst this was partly driven by fear of the disease itself and the devastating clinical consequences of HIV without treatment, we should acknowledge that both physicians and scientists have contributed to this stigma. Here, I highlight how this has been mediated through language and scientific definitions. Although these contributors have likely not been intentional, going forward, we need to learn from past experiences and carefully consider how, as clinicians, clinical researchers and scientists, our work can focus on reducing the stigma and discrimination that has surrounded HIV for so many decades. 

(more…)

A deep dive into 30 years of progress and challenges

Professor Jonathan Valabhji

Diabetes now affects over half a billion people globally, including 3.8 million people in England. Type 2 diabetes, which accounts for 90-95% of all cases, has obesity as its primary modifiable risk factor. Expanding waistlines, both nationally and globally, have driven a steady increase in type 2 diabetes rates in recent decades. To mark World Diabetes Day, Professor Jonathan Valabhji OBE, from the Department of Metabolism, Digestion and Reproduction, reflects on his 30 years of experience in the field, in clinical practice, in national leadership, and in clinical and epidemiological research.  

My background in Diabetes research and clinical practice 

I qualified as a doctor in 1990 from St Bartholomew’s Hospital Medical College, London. I undertook specialist training in diabetes, endocrinology, and general medicine in North-West London, and landed at Imperial College in 1997 to undertake my MD (Doctor of Medicine degree) as a British Heart Foundation Junior Research Fellow. In those early years, I was interested in cardiovascular disease in diabetes, which at that point was responsible for the majority of deaths in people with diabetes. My work centred on understanding the paradox in type 1 diabetes: although patients often displayed healthy cholesterol profiles, they were at elevated risk of heart attacks and strokes. I spent 3 years in a lipid laboratory, using ultracentrifugation (a technique used to separate and isolate particles based on their density) to isolate high-density lipoprotein (HDL) cholesterol particles from blood samples, to try to disentangle the paradox.  

Population-level progress in cardiovascular health  

While I like to think that some of that early research advanced the field a little, it was other epidemiological and societal factors that saw cardiovascular disease fall in people with diabetes over the next two decades. Public health initiatives, such as reduced smoking rates, and improved management of blood glucose, blood pressure, and cholesterol, have collectively driven a marked decrease in cardiovascular complications, resulting in longer lifespans for people with diabetes. However, with this success came new challenges, as other and multiple long-term conditions (MLTCs) have increasingly become leading causes of illness and death. This has complicated care for patients, healthcare professionals, and the NHS.  At the same time, obesity has driven younger onset of type 2 diabetes, contributing to accelerated development of MLTCs at younger ages. 

(more…)